ALISO VIEJO, Calif. / Oct 29, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% year-over-year... Read More

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for Patients Afflicted by This Sight-Threatening Rare Disease Epioxa Expected to Be Commercially Available in Q1 2026 ALISO VIEJO, Calif. / Oct 20, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical... Read More

ALISO VIEJO, Calif. / Oct 14, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-20,... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Oct 08, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The company’s... Read More

Planned Investment of $80+ Million in 200,000 Square-Foot State-of-the-Art Facility Supports Glaukos’ Long-Term Growth Plans and Reinforces Commitment to U.S. Manufacturing ALISO VIEJO, Calif. / Sep 25, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today... Read More

ALISO VIEJO, Calif. / Aug 13, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and... Read More

ALISO VIEJO, Calif. / Jul 30, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jul 09, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company’s... Read More

Regulatory Clearances Support Glaukos’ Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company’s First Regulatory Clearances Under the New EU Regulatory Framework ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders... Read More

ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10 th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET... Read More

ALISO VIEJO, Calif. / May 13, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at... Read More

ALISO VIEJO, Calif. / Apr 30, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a... Read More

ALISO VIEJO, Calif. / Apr 23, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held... Read More

ALISO VIEJO, Calif. / Apr 16, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Apr 09, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company’s... Read More

Industry Leaders Partner to Advance Vision Testing and Digital Solutions to Expand Patient Access to Eye Care Globally ALISO VIEJO, Calif. / Mar 11, 2025 / Business Wire / Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR’s new wearable vision testing platform - Inspire ® . This collaboration unites RadiusXR’s innovative visual field platform and... Read More

PDUFA Date Set for October 20, 2025 ALISO VIEJO, Calif. / Feb 24, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted... Read More

ALISO VIEJO, Calif. / Feb 20, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28%... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jan 23, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The... Read More

ALISO VIEJO, Calif. / Jan 14, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose ® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two... Read More

ALISO VIEJO, Calif. / Dec 23, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ ( Epi-on ), its next-generation corneal cross-linking iLink... Read More

ALISO VIEJO, Calif. / Dec 17, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco,... Read More

ALISO VIEJO, Calif. / Nov 08, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40... Read More

ALISO VIEJO, Calif. / Nov 04, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include: Record net sales of $96.7 million increased 24%... Read More

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the Ophthalmic Community and Patients with the First FDA-Approved, Non-Invasive Drug Therapy Alternative for Keratoconus ALISO VIEJO, Calif. /... Read More

ALISO VIEJO, Calif. / Oct 14, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-21, 2024,... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Oct 09, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company’s... Read More

ALISO VIEJO, Calif. / Aug 16, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at... Read More

ALISO VIEJO, Calif. / Jul 31, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2024. Key highlights include: Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jul 10, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company’s... Read More

ALISO VIEJO, Calif. / Jun 14, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 2.75% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Pursuant to these Exchange Agreements, the company agreed,... Read More

ALISO VIEJO, Calif. / May 28, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference on Wednesday, June... Read More

ALISO VIEJO, Calif. / May 01, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year.... Read More

ALISO VIEJO, Calif. / Apr 16, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Apr 10, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management... Read More

New J-code for iDose TR ® , J7355, set to become effective July 1, 2024 ALISO VIEJO, Calif. / Apr 03, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent... Read More

ALISO VIEJO, Calif. / Apr 01, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in... Read More

ALISO VIEJO, Calif. / Feb 21, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16%... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jan 31, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The... Read More

ALISO VIEJO, Calif. / Jan 09, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023. Preliminary and unaudited total net sales for the fourth quarter and... Read More

ALISO VIEJO, Calif. / Dec 20, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco,... Read More

Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval based on robust Phase 3 clinical program consisting of two pivotal studies that randomized 1,150 subjects across 89 clinical sites Glaukos to host... Read More

ALISO VIEJO, Calif. / Nov 07, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City. A live and... Read More

ALISO VIEJO, Calif. / Nov 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a... Read More

ALISO VIEJO, Calif. / Oct 31, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Oct 11, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023. The company’s... Read More

ALISO VIEJO, Calif. / Aug 23, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA. A live and... Read More

ALISO VIEJO, Calif. / Aug 02, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include: Net sales of $80.4 million in Q2 2023 increased 11% year-over-year. Glaucoma net... Read More

Advancing Next-Generation Wearable Patient Engagement and Diagnostic Technology Designed to Enable More Efficient Detection of Eye Diseases ALISO VIEJO, Calif. / Jul 17, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jul 12, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2023 financial results after the market close on Wednesday, August 2, 2023. The company’s... Read More

Enrollment Completion Achieved in Less Than Six Months from Trial Commencement, Ahead of Original Timing Expectations Phase 3 Confirmatory Trial Results Together with Already-Completed First Phase 3 Trial Expected to Support Glaukos’ Targeted NDA Submission for Epioxa by the End of 2024 ALISO VIEJO, Calif. / Jun 05, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical... Read More

ALISO VIEJO, Calif. / May 24, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 43 rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 10:40 a.m. CT in Chicago, IL.... Read More

PDUFA Date Set for December 22, 2023 ALISO VIEJO, Calif. / May 05, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted... Read More

ALISO VIEJO, Calif. / May 03, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported... Read More

ALISO VIEJO, Calif. / May 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held... Read More

ALISO VIEJO, Calif. / Apr 19, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2022 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Apr 12, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The company’s management... Read More

ALISO VIEJO, Calif. / Feb 27, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose ® TR . iDose TR is a micro-invasive intraocular implant... Read More

ALISO VIEJO, Calif. / Feb 22, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include: Net sales of $71.2 million in Q4 2022. Glaucoma net sales of... Read More

ALISO VIEJO, Calif. / Feb 15, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City. A live and archived... Read More

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Feb 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The... Read More

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose ® TR (travoprost intraocular implant) in subjects who had previously been... Read More

Commencement of Subject Enrollment in Epioxa™ Phase 3 Confirmatory Trial Promising Phase 2a Results for GLK-301 (iLution – Dry Eye Disease) Support Planned Phase 2b Study to Commence in 2023 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for... Read More

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41 st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for this event will be... Read More